The ferocity of China’s biopharmaceutical investment boom this year – fuelled by record-breaking licensing of commercial rights to global giants…
Read More »chemotherapy
Evive Biotech, a unit of Shenzhen-listed Yifan Pharmaceutical, aims to break the dominance of American drugs developer Amgen in the…
Read More »